Clinical Trial Update: A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Nal-IRI with 5-FU, Levofolinic acid, and Oxaliplatin in patients with resectable pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• 5-FU (5-fluorouracil)
• Levofolinic acid (levofolinic acid)
• Nal-IRI (nanoliposomal irinotecan)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Centro Ricerche Cliniche di Verona | Conditions: Pancreatic Adenocarcinoma | Phase 2 | Status: UNKNOWN